{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:53:20Z","timestamp":1786136000883,"version":"build-2736575974"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Ruxolitinib, a Janus kinase (JAK) inhibitor, may increase the risk of tuberculosis infection by suppressing cellular immunity. Tuberculosis associated with ruxolitinib has generally been reported as disseminated or multisystem disease. However, no previous cases of primary bone tuberculosis secondary to ruxolitinib have been reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 68-year-old female patient had been taking ruxolitinib for over 2 years for primary thrombocythaemia and developed recurrent high fever without other localizing symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>\n                      Imaging studies revealed multiple areas of bone destruction with increased metabolic activity throughout the skeleton (sacroiliac joints, humeral heads), necessitating differential diagnosis from malignant tumors. Following exclusion of hematological malignancies via bone marrow aspiration, Xpert MTB\/RIF (X-pert) testing of the bone lesion tissue confirmed\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      infection. Concurrently, bronchial alveolar lavage fluid analysis ruled out active pulmonary tuberculosis, leading to a definitive diagnosis of isolated primary bone tuberculosis confined to the skeletal system.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Standard four-drug antituberculosis therapy was administered once daily: isoniazid 200\u2009mg, rifampicin 450\u2009mg, pyrazinamide 1125\u2009mg, and ethambutol 625\u2009mg, while ruxolitinib was continued for the underlying myeloproliferative disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Follow-up MRI examinations of the right humeral head and sacroiliac joints at 4 and 5 months post-tuberculosis treatment revealed a marked reduction in lesion size and decreased edema at both sites, consistent with an effective therapeutic response..<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case shows that ruxolitinib-associated tuberculosis can present as an isolated skeletal infection. It may occur without any pulmonary or systemic involvement. Latent tuberculosis screening should be performed before initiating ruxolitinib. Vigilance for extrapulmonary tuberculosis should be maintained throughout therapy. Unexplained bone lesions in JAK-inhibitor users warrant multidisciplinary evaluation. Empirical fluoroquinolone use before diagnosis may transiently mask the disease and delay recognition. Finally, CYP3A4-mediated interactions should be anticipated when rifampicin-based therapy is combined with ruxolitinib.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050140","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T18:00:57Z","timestamp":1786125657000},"page":"e50140","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Rare primary bone tuberculosis associated with ruxolitinib therapy: A case report and literature review"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7698-8205","authenticated-orcid":false,"given":"Liang-Yan","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9007-7702","authenticated-orcid":false,"given":"Fan","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Liang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4133-7334","authenticated-orcid":false,"given":"Ting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hangzhou Xixi Hospital, Hangzhou Sixth People\u2019s Hospital, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, 310023, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260807","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J Hematol Oncol"},{"key":"R2-20260807","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-20260807","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review.","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"R4-20260807","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases.","volume":"80","author":"Xin","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R5-20260807","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/ijmy.ijmy_186_21","article-title":"The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections.","volume":"10","author":"Ghanavi","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R6-20260807","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.4049\/jimmunol.1400620","article-title":"SHP-1 plays a crucial role in CD40 signaling reciprocity.","volume":"193","author":"Khan","year":"2014","journal-title":"J Immunol"},{"key":"R7-20260807","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.4049\/jimmunol.1900311","article-title":"IL-11 induces encephalitogenic Th17 cells in multiple sclerosis and experimental autoimmune encephalomyelitis.","volume":"203","author":"Zhang","year":"2019","journal-title":"J Immunol"},{"key":"R8-20260807","doi-asserted-by":"crossref","first-page":"e2221007120","DOI":"10.1073\/pnas.2221007120","article-title":"IL-11 induces NLRP3 inflammasome activation in monocytes and inflammatory cell migration to the central nervous system.","volume":"120","author":"Seyedsadr","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R9-20260807","doi-asserted-by":"crossref","first-page":"1138145","DOI":"10.3389\/fimmu.2023.1138145","article-title":"Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.","volume":"14","author":"Tarique","year":"2023","journal-title":"Front Immunol"},{"issue":"Pt 3","key":"R10-20260807","doi-asserted-by":"crossref","first-page":"126823","DOI":"10.1016\/j.ijbiomac.2023.126823","article-title":"Characterization of pH-induced conformational changes in recombinant DENV NS2B-NS3pro.","volume":"253","author":"Hisamuddin","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"R11-20260807","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s13555-024-01203-2","article-title":"Biologics versus JAK inhibitors. Part II: risk of infections. a narrative review.","volume":"14","author":"Mansilla-Polo","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R12-20260807","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/omcr\/omaa025","article-title":"A report of two challenging cases of bone infection: mycobacterium tuberculosis. How to manage.","volume":"2020","author":"Elghoul","year":"2020","journal-title":"Oxford Med Case Reports"},{"key":"R13-20260807","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.jcot.2021.101707","article-title":"Sacroiliac joint tuberculosis revisited - A clinico-radiological review.","volume":"24","author":"Jain","year":"2022","journal-title":"J Clin Orthop Trauma"},{"key":"R14-20260807","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.rmr.2025.06.005","article-title":"Ruxolitinib, disseminated tuberculosis and primary myelofibrosis: a case study.","volume":"42","author":"G\u00e9rard","year":"2025","journal-title":"Rev Mal Respir"},{"key":"R15-20260807","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ajh.24976","article-title":"Ruxolitinib-associated infections: a systematic review and meta-analysis.","volume":"93","author":"Lussana","year":"2018","journal-title":"Am J Hematol"},{"key":"R16-20260807","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"R17-20260807","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded\u2010access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.","volume":"189","author":"Al\u2010Ali","year":"2020","journal-title":"Br J Haematol"},{"key":"R18-20260807","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1080\/14796694.2025.2550924","article-title":"Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.","volume":"21","author":"Aruga","year":"2025","journal-title":"Future Oncol"},{"key":"R19-20260807","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijid.2019.01.002","article-title":"Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera.","volume":"80","author":"Lescuyer","year":"2019","journal-title":"Int J Infect Dis"},{"key":"R20-20260807","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ijtb.2021.06.003","article-title":"Ruxolitinib and tuberculosis: a case report with brief review.","volume":"69","author":"Tiwari","year":"2022","journal-title":"Indian J Tuberc"},{"key":"R21-20260807","doi-asserted-by":"crossref","first-page":"e37653","DOI":"10.1097\/MD.0000000000037653","article-title":"Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: a case report and literature review.","volume":"103","author":"Chen","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R22-20260807","doi-asserted-by":"crossref","first-page":"e00892","DOI":"10.1016\/j.idcr.2020.e00892","article-title":"Necessity to screen and treat latent tuberculosis before ruxolitinib treatment\u2014Ruxolitinib-associated disseminated tuberculosis: a case report and literature review.","volume":"21","author":"Hirai","year":"2020","journal-title":"IDCases"},{"key":"R23-20260807","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"key":"R24-20260807","first-page":"284168","article-title":"Ruxolitinib associated tuberculosis presenting as a neck lump.","volume":"2015","author":"Shamil","year":"2015","journal-title":"Case Rep Infect Dis"},{"key":"R25-20260807","doi-asserted-by":"crossref","first-page":"bcr2016217854","DOI":"10.1136\/bcr-2016-217854","article-title":"Idiopathic myelofibrosis with disseminated hepatosplenic, mesenteric, renal and pulmonary extramedullary haematopoeisis, portal hypertension and tuberculosis: initial presentation and 2 years follow-up.","volume":"2016","author":"Panda","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R26-20260807","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2169\/internalmedicine.9165-17","article-title":"Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: a case report and review of the literature.","volume":"57","author":"Tsukamoto","year":"2017","journal-title":"Intern Med"},{"key":"R27-20260807","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2147\/IDR.S249030","article-title":"Tuberculosis peritonitis during treatment of polycythemia vera with ruxolitinib.","volume":"13","author":"Sakiyama","year":"2020","journal-title":"Infect Drug Resistance"},{"key":"R28-20260807","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.hemonc.2020.02.003","article-title":"Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis.","volume":"14","author":"Khalid","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R29-20260807","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000515430","article-title":"Isolated nodal TBC reactivation in a patient with post-thrombocythemia myelofibrosis treated with ruxolitinib: case report and review of the literature.","volume":"66","author":"Santoro","year":"2021","journal-title":"Chemotherapy"},{"key":"R30-20260807","first-page":"e63791","article-title":"Miliary TB and COVID-19 coinfection in a patient with a history of post-polycythemia vera myelofibrosis treated with ruxolitinib: a case report.","volume":"16","author":"Loutsou","year":"2024","journal-title":"Cureus"},{"key":"R31-20260807","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.","volume":"52","author":"Shi","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R32-20260807","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.ijid.2010.11.008","article-title":"Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis.","volume":"15","author":"Chen","year":"2011","journal-title":"Int J Infect Dis"},{"key":"R33-20260807","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis.","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:01:41Z","timestamp":1786132901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":33,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050140","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"2025-10-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}